A meta-analysis of 28 clinical trials enrolling more than 21,000 patients with type 2 diabetes also showed that DPP-4 inhibitors reduced fracture risk compared to placebo and other antidiabetic treatments [145]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.